Previse's New Prognostic Assay, Esopredict™, is a
Medical Breakthrough Available for Gastroenterologists in
Identifying Barrett's esophagus Patients at Risk for Developing
Cancer
BALTIMORE, May 15, 2024
/PRNewswire/ -- Previse, maker of Esopredict, a clinically
available test that analyzes the methylation of biomarkers to
assess the risk of esophageal cancer developing in patients with
Barrett's Esophagus (BE), announced today the acceptance of a
poster presentation at the upcoming Digestive Disease Week (DDW)
2024 being held May 18-21 in
Washington, DC and virtually.
Details for the presentation are as follows:
Session Type: Poster Session
Session Title: Barrett's Esophagus and Esophagogastric Junction
Neoplasia - Epidemiology, Risk Factors, Screening, Surveillance,
Treatment and Outcomes
Session Date & Time: May 19,
2024, from 12:30 PM to 1:30 PM
EDT (UTC-4)
Presentation Title: ACCURACY AND REPRODUCIBILITY OF ESOPREDICT,
A PROGNOSTIC ASSAY FOR HGD/EAC RISK STRATIFICATION IN PATIENTS WITH
BARRETT'S ESOPHAGUS
The presentation will focus on the notable performance
characteristics of Esopredict, including its precision, accuracy,
and reproducibility within the assay's target patient
population.
Daniel Lunz, Co-founder and CEO of Previse expressed, "At
Previse, we are committed to following science and applying the
rigor required to develop solutions that support effective cancer
prevention, detection, and treatment strategies that will save
lives. The analytical validation results being presented at DDW
demonstrate the robustness of Esopredict, the first and only DNA
methylation-based assay to provide important future cancer risk
insights to people living with Barrett's esophagus."
About Previse and Esopredict
Previse is a pioneering medical solutions company with a primary
focus on preventing and detecting esophageal cancer, one of the
deadliest cancers globally and the second most lethal in
the United States. Previse's
mission is to improve patient care by preventing, detecting, and
guiding treatment for upper GI diseases, including cancer.
Previse leverages groundbreaking biomarker technology developed
by Stephen Meltzer, M.D., and his GI
Early Detection Biomarker Lab at Johns Hopkins
University School of Medicine. This technology, backed by
funding from the National Institutes of Health (NIH) and decades of
research, forms the foundation of Previse's commitment to combating
esophageal cancer.
At the forefront of Previse's offerings is Esopredict, the first
DNA methylation-based assay designed to predict the risk of
progression to high-grade dysplasia or esophageal adenocarcinoma in
patients with Barrett's esophagus. With an impressive turnaround
time of ≤2 weeks after a sample is received, Esopredict empowers
gastroenterologists to tailor effective treatment strategies,
marking a pivotal advancement in the battle against esophageal
cancer.
For more information about Previse and Esopredict, please visit
www.previsedx.com.
About Digestive Disease Week
Digestive Disease Week® (DDW) is the largest international
gathering of physicians, researchers, and academics in the fields
of gastroenterology, hepatology, endoscopy, and gastrointestinal
surgery. Jointly sponsored by the American Association for the
Study of Liver Diseases (AASLD), the American Gastroenterological
Association (AGA) Institute, the American Society for
Gastrointestinal Endoscopy (ASGE), and the Society for Surgery of
the Alimentary Tract (SSAT), DDW is an in-person and virtual
meeting from May 18-2, 2024. The
meeting showcases more than 4,000 abstracts and hundreds of
lectures on the latest advances in GI research, medicine, and
technology. More information can be found at www.ddw.org.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/previse-announces-upcoming-presentation-at-digestive-disease-week-ddw-2024-302146353.html
SOURCE Previse